Results 21 to 30 of about 7,321 (205)

Case series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequelae of COVID (PASC)

Frontiers in Medicine, 2023
Post-acute sequelae of COVID (PASC), or long COVID, is a multisystem complication of SARS-CoV-2 infection that continues to debilitate millions worldwide thus highlighting the public health importance of identifying effective therapeutics to alleviate ...
Bruce K. Patterson, Ram Yogendra, Jose Guevara-Coto, Rodrigo A. Mora-Rodriguez, Eric Osgood, John Bream, Purvi Parikh, Mark Kreimer, Devon Jeffers, Cedric Rutland, Gary Kaplan, Michael Zgoda   +11 more
doaj   +1 more source

Virological failure of patients on maraviroc-based antiretroviral therapy [PDF]

, 2015
International audienceOBJECTIVES: Virological failure (VF) in patients on maraviroc-based treatment has been associated with altered HIV tropism and resistance to maraviroc.
Marcelin, Anne Geneviève, Amiel, Corinne, Peytavin, Gilles, Descamps, Diane, Izopet, Jacques, Trabaud, Mary Anne, Delaugerre, Constance, Raymond, Stéphanie, Soulie, Cathia, Maillard, Anne, Desbois, Delphine, Bellecave, Pantxika   +11 more
core   +1 more source

Interactions between Alcohol and the HIV Entry Inhibitor Maraviroc [PDF]

, 2013
BACKGROUND: Alcohol use is common among people with HIV, and beliefs about alcohol interactions with medications predict decreased medication adherence, risking drug-resistant mutations.
Rainey, Petrie M, Aweeka, Francesca T, Lum, Paula J, Beatty, George W, Gruber, Valerie A, McCance-Katz, Elinore F   +5 more
core   +1 more source

Chemokine Receptor 5 Antagonism Causes Reduction in Joint Inflammation in a Collagen-Induced Arthritis Mouse Model

Molecules, 2021
Rheumatoid arthritis (RA) is a chronic inflammatory disease mainly affecting the synovial joints. A highly potent antagonist of C-C chemokine receptor 5 (CCR5), maraviroc (MVC), plays an essential role in treating several infectious diseases but has not ...
Mushtaq A. Ansari, Ahmed Nadeem, Saleh A. Bakheet, Sabry M. Attia, Mudassar Shahid, Faris S. Alyousef, Mohammed A. Alswailem, Mohammed Alqinyah, Sheikh F. Ahmad   +8 more
doaj   +1 more source

A drug interaction study investigating the effect of Rifabutin on the pharmacokinetics of Maraviroc in healthy subjects.

PLoS ONE, 2019
Effects of steady-state rifabutin on the pharmacokinetics of steady-state maraviroc were investigated in fourteen healthy adult female and male volunteers. Maraviroc 300 mg twice daily (BID) was given orally with food for fifteen days.
M Ghannad, M Dennehy, C la Porte, I Seguin, D Tardiff, R Mallick, E Sabri, G Zhang, S Kanji, D W Cameron   +9 more
doaj   +1 more source

Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials.

PLoS ONE, 2018
Detailed clonal phenotypic/genotypic analyses explored viral-escape mechanisms during maraviroc-based therapy in highly treatment-experienced participants from the MOTIVATE trials. To allow real-time assessment of samples while maintaining a blind trial,
Marilyn Lewis, Julie Mori, Jonathan Toma, Mike Mosley, Wei Huang, Paul Simpson, Roy Mansfield, Charles Craig, Elna van der Ryst, David L Robertson, Jeannette M Whitcomb, Mike Westby   +11 more
doaj   +1 more source

Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification

Journal of Virus Eradication, 2015
Background: It is unclear whether intensification of standard highly active antiretroviral therapy (HAART) with entry and integrase inhibitors during acute HIV infection (AHI) could yield greater benefits in reducing markers for HIV reservoir size and ...
Jintanat Ananworanich, Nicolas Chomont, James L.K. Fletcher, Suteeraporn Pinyakorn, Alexandra Schuetz, Irini Sereti, Rungsun Rerknimitr, Robin Dewar, Eugene Kroon, Claire Vandergeeten, Rapee Trichavaroj, Nitiya Chomchey, Thep Chalermchai, Nelson L. Michael, Jerome H. Kim, Praphan Phanuphak, Nittaya Phanuphak   +16 more
doaj   +1 more source

Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates. [PDF]

PLoS ONE, 2015
Maraviroc activity against HIV-2, a virus naturally resistant to different HIV-1 antiretroviral drugs, has been recently demonstrated. The aim of this study was to assess HIV-2 susceptibility to cenicriviroc, a novel, once-daily, dual CCR5 and CCR2 ...
Benoit Visseaux, Charlotte Charpentier, Gilles Collin, Mélanie Bertine, Gilles Peytavin, Florence Damond, Sophie Matheron, Eric Lefebvre, Françoise Brun-Vézinet, Diane Descamps, ANRS CO5 HIV-2 Cohort   +10 more
doaj   +1 more source

Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals.

PLoS ONE, 2014
BackgroundThe effect of maraviroc on the maintenance and the function of HIV-1-specific T cell responses remains unknown.MethodsSubjects recently infected with HIV-1 were randomized to receive anti-retroviral treatment with or without maraviroc ...
Ai Kawana-Tachikawa, Josep M Llibre, Isabel Bravo, Roser Escrig, Beatriz Mothe, Jordi Puig, Maria C Puertas, Javier Martinez-Picado, Julia Blanco, Christian Manzardo, Jose M Miro, Aikichi Iwamoto, Anton L Pozniak, Jose M Gatell, Bonaventura Clotet, Christian Brander, MARAVIBOOST Investigators   +16 more
doaj   +1 more source

HIV-1 Entry, Inhibitors, and Resistance

Viruses, 2010
Entry inhibitors represent a new class of antiretroviral agents for the treatment of infection with HIV-1. While resistance to other HIV drug classes has been well described, resistance to this new class is still ill defined despite considerable clinical
Michael A. Lobritz, Annette N. Ratcliff, Eric J. Arts   +2 more
doaj   +1 more source